Description
• রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Long Description:
Indications:
Otezol 150 mg is indicated for the treatment of advanced non-small cell lung cancer (NSCLC), urothelial carcinoma, and other cancers responsive to PD-L1 inhibition.
Pharmacology:
Otezolizumab (Otezol) is an anti-PD-L1 monoclonal antibody that works by blocking the PD-L1 protein on tumor cells, enabling the immune system to better recognize and attack the cancer cells.
Dosage:
The recommended dose is 1200 mg administered by intravenous infusion every 3 weeks.
Administration:
Administer intravenously. The infusion is given over 60 minutes, and should be performed by a healthcare professional.
Interaction:
There are no known major drug interactions with Otezol, but caution should be exercised when combining with other immunotherapy agents.
Contraindications:
-
Known hypersensitivity to Otezolizumab or any of its components
-
Active autoimmune diseases or immunodeficiency disorders
-
Severe infections or other medical conditions that may compromise immune response
Side Effects:
Common side effects include fatigue, nausea, diarrhea, and fever. Serious side effects may include immune-related adverse reactions, such as lung inflammation, liver problems, or endocrine disorders.
Pregnancy & Lactation:
Not recommended during pregnancy unless absolutely necessary. It is not known whether Otezol is excreted in human milk, so breastfeeding is not advised.
Precautions & Warnings:
Monitor patients for signs of immune-related adverse reactions and infections. Patients with pre-existing autoimmune conditions should use this drug under close supervision.
Therapeutic Class:
Immunotherapy, Monoclonal antibody
Storage Conditions:
Store in a refrigerator (2°C to 8°C). Do not freeze. Keep the vial in the outer carton to protect from light. Keep out of reach of children.
.jpeg)
 100ML.jpg)
.jpg)
.jpg)
 10P.jpg)
Change Language